Patents by Inventor Perry Francis Bartlett
Perry Francis Bartlett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9890358Abstract: The present invention relates to a latent neural stem cell population which is capable of activation by membrane depolarization of a neural cell population, isolation and culture of same, and uses thereof.Type: GrantFiled: April 10, 2008Date of Patent: February 13, 2018Assignee: The University of QueenslandInventors: Tara Louise Walker, Perry Francis Bartlett
-
Patent number: 8790889Abstract: A method of activating a latent neural precursor cell population, comprising: (1) providing a neural cell population derived from the hippocampus; (2) introducing the neural cell population to a neurosphere-forming culture medium; and (3) activating the latent precursor cell population by treatment with a ?3 adrenergic receptor agonist.Type: GrantFiled: December 21, 2010Date of Patent: July 29, 2014Assignee: The University of QueenslandInventors: Dhanisha Jhaveri, Perry Francis Bartlett
-
Publication number: 20130004984Abstract: A method of activating a latent neural precursor cell population, comprising: (1) providing a neural cell population derived from the hippocampus; (2) introducing the neural cell population to a neurosphere-forming culture medium; and (3) activating the latent precursor cell population by treatment with a ?3 adrenergic receptor agonist.Type: ApplicationFiled: December 21, 2010Publication date: January 3, 2013Applicant: The University of QueenslandInventors: Dhanisha Jhaveri, Perry Francis Bartlett
-
Patent number: 8299027Abstract: The present invention relates generally to a method for modulating cell survival. Modulation of cell survival includes inducing, enhancing or otherwise promoting cell survival such as the survival of neural cells as well as facilitating cell death such as the death of targeted cancer cells. The modulation of cell survival is mediated by a region identified on the p75 neurotrophin receptor (p75NTR) required for death signalling. The present invention further provides genetic molecules which encode the death signalling region of p75NTR which are useful in antagonising death signal function as well as promoting cell death when expressed in targeted cells. The present invention also contemplates recombinant peptides, polypeptides and proteins as well as chemical equivalents, derivatives and homologues thereof which comprise the death signalling portion of p75NTR. Particularly useful molecules of the present invention comprise peptides corresponding to soluble forms of the death signalling portion of p75NTR.Type: GrantFiled: September 17, 2010Date of Patent: October 30, 2012Assignee: The University of QueenslandInventors: Perry Francis Bartlett, Elizabeth Jane Coulson, Katrina Fieldew, Manuel Baca, Trevor Kilpatrick, Cheema Surindar
-
Publication number: 20120195860Abstract: The present invention relates to a latent neural stem cell population which is capable of activation by membrane depolarization of a neural cell population, isolation and culture of same, and uses thereof.Type: ApplicationFiled: April 10, 2008Publication date: August 2, 2012Inventors: Tara Louise Walker, Perry Francis Bartlett
-
Publication number: 20110172143Abstract: The present invention relates generally to a method for modulating cell survival. Modulation of cell survival includes inducing, enhancing or otherwise promoting cell survival such as the survival of neural cells as well as facilitating cell death such as the death of targeted cancer cells. The modulation of cell survival is mediated by a region identified on the p75 neurotrophin receptor (p75NTR) required for death signalling. The present invention further provides genetic molecules which encode the death signalling region of p75NTR which are useful in antagonising death signal function as well as promoting cell death when expressed in targeted cells. The present invention also contemplates recombinant peptides, polypeptides and proteins as well as chemical equivalents, derivatives and homologues thereof which comprise the death signalling portion of p75NTR. Particularly useful molecules of the present invention comprise peptides corresponding to soluble forms of the death signalling portion of p75NTR.Type: ApplicationFiled: September 17, 2010Publication date: July 14, 2011Applicant: University of Queensland, TheInventors: Perry Francis Bartlett, Elizabeth Jane Coulson, Katrina Fieldew, Manuel Baca, Trevor Kilpatrick, Cheema Surindar
-
Patent number: 7919471Abstract: The present invention relates generally to a method for modulating cell survival. Modulation of cell survival includes inducing, enhancing or otherwise promoting cell survival such as the survival of neural cells as well as facilitating cell death such as the death of targeted cancer cells. The modulation of cell survival is mediated by a region identified on the p75 neurotrophin receptor (p75NTR) required for death signalling. The present invention further provides genetic molecules which encode the death signalling region of p75NTR which are useful in antagonising death signal function as well as promoting cell death when expressed in targeted cells. The present invention also contemplates recombinant peptides, polypeptides and proteins s well as chemical equivalents, derivatives and homologues thereof which comprise the death signalling portion of p75NTR. Particularly useful molecules of the present invention comprise peptides corresponding to soluble forms of the death signalling portion of p75NTR.Type: GrantFiled: August 18, 2004Date of Patent: April 5, 2011Assignee: The University of QueenslandInventors: Perry Francis Bartlett, Elizabeth Jane Coulson, Katrina Fieldew, Manuel Baca, Trevor Kilpatrick, Cheema Surindar
-
Patent number: 7435586Abstract: The present invention relates generally to a method for the generation of a substantially homogeneous population of undifferentiated cells. More particularly, the present invention relates to the purification of a substantially homogeneous population of stem cells and their progenitor or precursor cells. Even more particularly, the present invention provides a population of neural stem cells (NSCs). The subject invention is particularly directed to NSCs and precursor cells with the capacity to differentiate into cells and cell lineages required for the development, maintenance or repair of the central nervous system in an animal such as a mammal. The present invention is further directed to NSCs and progenitor and/or precursor cells which are capable of proliferation and differentiation into multiple cell lineages, such as but not limited to neurons, oligodendrocytes, glia and astrocytes.Type: GrantFiled: May 31, 2002Date of Patent: October 14, 2008Assignee: The University of QueenslandInventors: Perry Francis Bartlett, Rodney Lee Rietze
-
Publication number: 20040235158Abstract: The present invention relates generally to a method for the generation of a substantially homogeneous population of undifferentiated cells. More particularly, the present invention relates to the purification of a substantially homogeneous population of stem cells and their progenitor or precursor cells. Even more particularly, the present invention provides a population of neural stem cells (NSCs). The subject invention is particularly directed to NSCs and precursor cells in the capacity to differentiate into cells and cell lineages required for the development, maintenance or repair of the central nervous system in an animal such as a mammal. The present invention is further directed to NSCs and progenitor and/or precursor cells which are capable of proliferation and differentiation into multiple cell lineages, such as but not limited to neurons, oligodendrocytes, glia and astrocytes.Type: ApplicationFiled: June 29, 2004Publication date: November 25, 2004Inventors: Perry Francis Bartlett, Rodney Lee Rietze
-
Publication number: 20030162700Abstract: The present invention relates generally to a method of treatment and to agents useful for same. More particularly, the present invention contemplates a method for the treatment and/or prophylaxis of a nervous system disease, demyelinating disease and/or an inflammatory disease of either the central or peripheral nervous system such as but not limited to an encephalopathic condition and even more particularly an encephalomyelopathic condition. The present invention further provides the use of leukemia inhibitory factor or derivatives, homologous or analogues thereof in the manufacture of a medicament for the treatment and/or prophylaxis of a nervous system disease, demyelinating disease and/or an inflammatory disease of either the central or peripheral nervous system such as but not limited to an encephalopathic and more particularly an encephalomyelopathic condition.Type: ApplicationFiled: April 9, 2003Publication date: August 28, 2003Inventors: Kylie Ann-Maree Shipham, Tamara Ann Michelle Bucci, Helmut Butzkueven, Trevor John Kilpatrick, Perry Francis Bartlett
-
Publication number: 20020137188Abstract: The present invention relates generally to a method for modulating cell survival. Modulation of cell survival includes inducing, enhancing or otherwise promoting cell survival such as the survival of neural cells as well as facilitating cell death such as the death of targeted cancer cells. The modulation of cell survival is mediated by a region identified on the p75 neurotrophin receptor (p75NTR) required for death signalling. The present invention further provides genetic molecules which encode the death signalling region of p75NTR which are useful in antagonizing death signal function as well as promoting cell death when expressed in targeted cells. The present invention also contemplates recombinant peptides, polypeptides and proteins s well as chemical equivalents, derivatives and homologues thereof which comprise the death signalling portion of p75NTR. Particularly useful molecules of the present invention comprise peptides corresponding to soluble forms of the death signalling portion of p75NTR.Type: ApplicationFiled: March 30, 2001Publication date: September 26, 2002Applicant: The Walter and Eliza Hall Institute of Medical ResearchInventors: Perry Francis Bartlett, Elizabeth Jane Coulson, Katrina Fieldew, Manuel Baca, Trevor Kilpatrick, Cheema Surindar